BridgeMD
Early optimization of ceftazidine dosing regimen in critical care : FORTOPTIM_1
EU CTIS ID: 2024-519783-41-00
What this study is testing
to evaluate a ceftazidime regimen optimized for rapid attainment and maintenance of target concentration in the critical care patient versus the standard regimen.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient at least 18 years old
- Patient hospitalized in critical care for an expected duration of at least 72 hours, with an infection for which initiation of ceftazidime therapy is being considered
- Patient with arterial catheter for blood sampling
- Patient affiliated to or entitled under a social security scheme
You likely can't join if
- Pregnant, parturient and nursing women
- Person deprived of liberty, hospitalized without consent
- Adult subject to a legal protection measure (guardianship-curatorship)
- History of severe hypersensitivity to ceftazidime, other cephalosporins or any other type of beta-lactam
- Patients who have received ceftazidime within the last 72 hours
- Patients undergoing renal replacement therapy or whose CKD-EPI at the start of treatment is less than 15 ml/min
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.